• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Impact of Daily Aspirin for Prevention of Preeclampsia among Women with Chronic Hypertension

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • ACOG recommends 81 mg of aspirin per day, initiated between 12 and 16 weeks, to prevent preeclampsia in high risk groups, including those with chronic hypertension
  • Banala et al. (AJOG, 2020) assessed the effectiveness of aspirin for the prevention of superimposed preeclampsia and other adverse maternal and neonatal outcomes in women with chronic hypertension before and after the 2016 guideline was released

METHODS:

  • Retrospective cohort study (2014 to 2018)
  • Participants
    • Women with chronic hypertension who delivered at a single hospital
  • Exposures
    • Before ACOG 2016 guidelines
    • After ACOG 2016 guidelines
  • Data analysis
    • Subgroup analysis history of preeclampsia, and pregestational diabetes
  • Primary outcome
    • Incidence of superimposed preeclampsia
  • Secondary outcomes
    • Superimposed preeclampsia with or without severe features
    • Small for gestational age (SGA)
    • Preterm birth <37 weeks

RESULTS:

  • 457 pregnant women
    • Before 2016 guidelines group: 254 women
      • Offered daily aspirin: 7.0%
    • After 2016 guidelines group: 203 women
      • Offered daily aspirin: 70%
    • There were no significant differences in maternal demographics
  • There was no significant difference in overall incidence of superimposed preeclampsia between the two groups (P = 0.79)
    • Before group: 34.3%
    • After group: 35.5%
  • Superimposed preeclampsia without severe features was decreased in the post ACOG 2016 group (p<0.01)
    • Before group: 12.6%
    • After group: 4.4%
  • Superimposed preeclampsia with severe features was significantly increased in the after group (P = 0.02)
    • Before group: 21.7%
    • After group: 31.0%
  • There were no significant differences in SGA neonates or preterm birth between groups
  • Subgroup analyses did not alter the results

CONCLUSION:

  • After the 2016 ACOG guidelines were implemented, 70% of the investigated cohort was offered aspirin
  • There were no significant differences in the incidence of superimposed preeclampsia, severe features, SGA, or preterm birth before and after the implementation of these new guidelines
  • The authors suggest the increase seen in preeclampsia with severe features in the post-ACOG group may be

…secondary to a learning curve after the publication of the 2013 ACOG guidelines with new diagnostic criteria and management for superimposed preeclampsia and superimposed preeclampsia with severe features

We hypothesize possible underdiagnosis in the subsequent few years (pre-ACOG group)

Learn More – Primary Sources:

Impact of the ACOG guideline regarding low-dose aspirin for prevention of superimposed preeclampsia in women with chronic hypertension

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

Aspirin Treatment for Women at Risk for Preeclampsia – ACOG and USPSTF Recommendations  
Is Aspirin for Early Preeclampsia Prophylaxis Cost-Effective?
Does Aspirin for Preeclampsia Risk Reduction Affect Biomarkers or Fetal Growth?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site